Synergistic Effect of Targeted Inhibition of MEK/ERK and PI3K/AKT Survival Signaling Pathways onInduction of Apoptosis in Melanoma

WANG Xin-yuan, CHENG Yao, DU Ji-pei.et al

Abstract

The treatment of metastatic melanoma by conventional chemotherapeutic agents remains unsatisfactory. The present study was undertaken to reveal the role of co-inhibition of survival signaling pathways in apoptosis of melanoma cells. Methods A panel of human melanoma cell lines and fresh melanoma isolates was assessed for their sensitivity to the MEK inhibitor U0126 and/or AKT inhibitor LY294002. The proliferation and apoptosis of the cells were examined after treatment with the inhibitors. Results Constitutive activation of ERK1/2 and AKT was closely related to concentrations of serum in the culture medium (extracellular signals). The sensitivity of melanoma cells to apoptosis induced by inhibition of MEK/ERK was not correlated with the active BRAF mutation (BRAFV600E. Inhibition of MEK/ERK predominantly induced apoptosis; whereas inhibition of PI3K/AKT primarily inhibited proliferation. Co-inhibition of MEK/ERK1/2 and PI3K/AKT synergistically induced apoptosis. Conclusion Co-targeting MEK/ERK and PI3K/AKT pathways may further improve treatment for melanoma.

 

Keywords: Melanoma, Synergistic effect, MEK/ERK PI3K/AKT 

 

Full Text:

PDF


References


Garbe С. Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma; current status and future prospects. Oncologist, 2011; 16( 1) ;5-24.

Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010;60(5) :277-300.

Hauschild A, Agarwala SS, Trefzer U, et al. Results of a Phase III , randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage [Y melanoma. J Clin Oncol, 2009;27( 17);2823-2830.

BollagG, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010;467(7315):596-599.

Nazarian R. Shi HB, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010;468(7326) :973-977.

Davies MA. The role of the PI3K-AKT pathway in melanoma. CancerJ, 2012;18(2); 142-147.

Yajima I, Kumasaka MY, Thang ND, et al. RAS/RAF/ MEK/ERK and Р13К/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract, 2012; 2012:354191. doi:10. 1155/2012/354191.

Yang H, Higgins B, Kolinsky K. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res, 2010; 70 (13);5518-5527.

Nguyen D, Zhang X, Hersey P. Regulation of TRAIL induced apoptosis of fresh melanoma isolates. Clin Cancer Res, 2001; 7 (3) j966s-973s.

Hodis E. Watson IR. Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2) ;251-263.

Paraiso KH. Xiang Y. Rebecca VW. et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011; 71 (7): 2750-2760.

Colombino M, Capone M, Lissia A. et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol, 2012; 30 ( 20): 2522- 2529.

Flaherty KT, Infante JR. Daud A. etui. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367( 18); 1694-1703.

Ott PA, Hamilton A, Min С, et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One, 2010; 5(12):el5588.

Poynter JN, Elder JT, Fullen DR, et al. BRAF and NR AS mutations in melanoma and melanocytic nevi. Melanoma Res, 2006;16(4):267-273.

Abdala-Valencia H, Berdnikovs S, Cook-Mills JM. Mechanisms for vascular cell adhesion molecule-1 activation of ERK1/2 during leukocyte transendothelial migration. PLoS One, 2011;6<10);e26706.

Pratsinis H, Constantinou V, Pavlakis K, et al. Exogenous and autocrine growth factors stimulate human intervertebral disc cell proliferation via the ERK and Akt pathways. J Orthop Res. 2012;30(6):958-964.

Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B- RAF - targeted melanoma cells. Cancer Res, 2010; 70(16): 6670-6681.

Aguissa-Toure A-H, Li G. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci, 2012;69(9): 1475-1491.

Mitsiades N, Chew SA, He B, et al. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf. MEK, and Akt kinases; rationale for personalized therapy. Invest Ophthalmol Vis Sci. 2011 ;52( 10) ;7248-7255.

Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov, 2014 ;4( 1); 94-109.

Davies MA, Stemke-Hale K, Lin E. et al. Integrated molecular and clinical analysis of АКТ activation in metastatic melanoma. Clin Cancer Res, 2009; 15(24);7538-7546.

Li Y. Takahashi M, Stork PJ. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal- regulated kinase and is inhibited by protein kinase a phosphorylation. J Biol Chem, 2013;288(38);27646-27657.


Refbacks

  • There are currently no refbacks.